78
Views
0
CrossRef citations to date
0
Altmetric
LetterToEditor Article

Second Long-Term Remission Achieved with Low-Dose Ara-C in Children with Relapsed Acute Nonlymphoblastic Leukemia

, , , , &
Pages 273-276 | Received 24 Jun 1986, Accepted 02 Oct 1986, Published online: 09 Jul 2009

References

  • Baccarani M. Low doses arabinosylcytosine for treatment of myelodysplastic syndromes and subacute leukemia. Leuk Res 1983; 7: 539–545
  • Housset M., Daniel M. T., Degos L. Small dose of Ara-C in the treatment of acute myeloid leukemia: Differentiation of leukemic myeloid cells. Br J Haematol 1981; 51: 125–129
  • Castaigne S. Traitement des hemopathies malignes par l'Aracytine a faible dose. Analyse des 159 cas. Nouv Rev Fr Hematol 1985; 27: 377–382
  • Perri R. T., Weisdorf D. J., Oken M. M. Low-dose ARA-C fails to enhance differentiation of leukaemic cells. Br J Haematol 1985; 59: 697–701
  • Jensen M. K., Ahlbom G. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukaemia. Scand J Haematol 1985; 34: 261–263
  • Hossfeld D. K., Weh H. J., Kleeberg U. R. Low dose cytarabine: Chromosomal findings suggesting its cytostatic as well as differentiating effect. Leuk Res 1985; 9: 329–330
  • Robert K. H. Acute myelogenous leukemia of unfavourable prognosis treated with retinoic acid, vitamin D3, alpha-interferon and low doses of cytosine arabinoside. Scand J Haematol 1986; 34: 61–74
  • Tilly H. Low dose cyiarabine: Persistence of a clonal abnormality during complete remission of acute nonlymphocytic leukemia. N Engl J Med 1986; 314: 246–247
  • Vecchi V. Impiego dell'Ara-C a basse dosi in una casistica di leucemie acute non linfoidi infantili. XIII Congresso Nazionale Associazione Italiana di Ematologia e Oncologia Pediatrica, Salice Terme (PV), April, 1986, 78, 28–29, (Abstr)
  • Cantu-Raynoldi A. Myelodysplastic syndromes in children: Observations on five cases. Pediatr Hematol Oncol 1984; 1: 71–75

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.